A Sense of Purpose: The Role of the Field Force During COVID-19

Posted by Chris Morgan on Wed, Mar 25, 2020

Namita Powers, Tania Lennon and Saby Mitra co-wrote this blog post with Chris Morgan.

The most pressing challenge for our society is the impact that the COVID-19 pandemic is having on the global population and economy. Protecting the health of the population is the chief priority, and then stabilizing the economy is the next most urgent priority. However, as pharmaceutical companies navigate this challenging landscape, we find that leadership also is grappling with how to keep field teams engaged and productive during this uncertain time. With travel restrictions, bans on community gathering, work-from-home guidance and understandable restrictions on access to healthcare settings, leaders from across the pharma industry are asking some key questions:


>
Read More

Is Coronavirus the Spark That Telehealth Needs?

Posted by Victoria Summers on Fri, Mar 13, 2020

Earlier this year, experts agreed that telehealth was poised to become mainstream in 2020. Spurred by broad access through smartphones and supported by health plans across the U.S., telehealth finally has the financial reimbursement and regulatory guidelines to enable patients and physicians to connect online. But now, COVID-19 has come on the scene. With the outbreak of the coronavirus in China and its rapid spread around the world, private companies and governments have encouraged people to quarantine themselves if they believe that they may have the virus. But how do patients know if they have it? If they suspect that they do have it, how can they access care in a way that doesn’t expose others? And if patients have health questions unrelated to coronavirus, wouldn’t they prefer to stay away from clinics and hospitals to decrease their risk of exposure?


>
Read More

The Future of Data in Pharma: Data Privacy, Data Ownership and Going Beyond the Pill

Posted by ZS Editors on Wed, Feb 12, 2020

Remember when big data was big news? Now all we hear about is AI, but that hasn’t made data any less relevant. Data is the fuel that feeds the business and the future of pharma, let alone AI. The world is becoming more and more data dependent while slow, tectonic shifts are under way across healthcare: There’s an increasing focus on the value of medical care over volume. The patient experience is becoming a higher priority. Data privacy and data ownership concerns are constantly threatening to upend the status quo with regulations that could be hugely disruptive.


>
Read More

Accelerating Market Access: Three Trends Shaping Pharma’s Future

Posted by Ed Schoonveld on Mon, Jan 06, 2020

Dean Hakanson co-wrote this blog post with Ed Schoonveld. This blog post was originally published on The Price of Global Health.

Is the demand for value-based care merely superficial? Are the industry’s decision-making and incentive systems built to encourage clinical innovation? How will pharma companies rethink their pipelines to improve poor commercialization efforts?


>
Read More

AI & Analytics Consumption: Insights on Demand

Posted by Arun Shastri on Wed, Oct 02, 2019

This blog post is the fifth in a series on the impact that AI will have on different business aspects of pharma.

The past few years have seen an explosion of data, and with it, the need to make use of it. Gathering and stitching together internal and external data sources presents one set of challenges, but what about the analysts who struggle to leverage all of this data? How can they keep up with increasing demands for data-driven insights from the entire organization? How can we empower the whole organization to have access to these critical insights? Here’s a hint: AI is part of the solution.


>
Read More